The CaV 2.3 encoded Ca2+ channel is one of the least well-known voltage-gated calcium channels in terms of physiology, pharmacology and clinical relevance. Epilepsy is a family of neurological disorders that are commo...The CaV 2.3 encoded Ca2+ channel is one of the least well-known voltage-gated calcium channels in terms of physiology, pharmacology and clinical relevance. Epilepsy is a family of neurological disorders that are common and harmful to human health. More and more studies such as gene knock-out experiment have demonstrated that the channel is related to epileptic seizure, including participating to plateau potential generation, regulating intracellular Ca2+ concentration, CaV 2.3 splice variant, interacting with some muteins. In addition, some antiepileptic drugs inhibit the epileptiform discharges by targeting CaV 2.3 voltage-gated calcium channel.展开更多
文摘为研制一种预防犬科动物狂犬病的新型疫苗,将含有狂犬病毒ERA株糖蛋白基因(Rabies glycoprotein,Rgp)表达盒的穿梭质粒pVAXΔE3Rgp中的Rgp表达盒克隆入犬2型腺病毒(Canine adenovirus type2,CAV2)骨架质粒pPoly2-CAV2中,获得重组质粒pPoly2-CAV2-ΔE3-Rgp,释放其基因组,转染MDCK细胞系,获得E3缺失区(Deletion of early protein3,ΔE3)含有Rgp表达盒的重组病毒CAV2-ΔE3-Rgp。该重组病毒能在MDCK细胞上产生典型的腺病毒细胞病变。通过酶切、PCR、基因测序,表明该重组病毒含有完整的Rgp表达盒。通过RT-PCR、Western blot等检测,表明该重组病毒能够表达Rgp抗原。用该重组病毒免疫犬,3次免疫后,可以诱导犬产生特异的抗CAV2HI抗体,其效价超过1∶256和抗狂犬病病毒(Rabies virus,RV)中和抗体,其效价超过0.50IU/mL。试验结果表明,获得的重组病毒免疫犬后,能够产生抗狂犬病毒和腺病毒的高效价保护性抗体,是一种有潜力的犬科动物狂犬病毒腺病毒二联疫苗候选株。
文摘The CaV 2.3 encoded Ca2+ channel is one of the least well-known voltage-gated calcium channels in terms of physiology, pharmacology and clinical relevance. Epilepsy is a family of neurological disorders that are common and harmful to human health. More and more studies such as gene knock-out experiment have demonstrated that the channel is related to epileptic seizure, including participating to plateau potential generation, regulating intracellular Ca2+ concentration, CaV 2.3 splice variant, interacting with some muteins. In addition, some antiepileptic drugs inhibit the epileptiform discharges by targeting CaV 2.3 voltage-gated calcium channel.
